Publications by authors named "James D Chambers"

Claim this Profile
R
Real-World Clinical Oncology Outcomes Associated With the Accelerated Approval Pathway.
Tu My To, Stacey Kowal, James D Chambers, William B Wong

Cancer Res Commun· December 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
U
U.S. health plan coverage of Neuromuscular Disease Therapies: An assessment of policy availability and restrictions.
A Alex Levine, Julia A Rucker, Alex Cockerham, Joel Cartner, James D Chambers

J Neuromuscul Dis· December 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
V
Variation in US Commercial Health Plan Coverage Restrictions for Cell and Gene Therapies.
James D Chambers, Julia A Rucker, Daniel E Enright, Molly T Beinfeld, Peter J Neumann

JAMA· November 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
The unintended consequences of the inflation reduction act on biosimilar market incentives and Medicare savings.
Molly T Beinfeld, Priyanka Ghule, Fariel LaMountain, William Wong, Stella Ko, James D Chambers

Health Aff Sch· November 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Drug Coverage Policies And Clinical Guidelines Alignment: Most Coverage Decisions Include Additional Restrictions.
Julia A Rucker, Molly T Beinfeld, Katherine A Clifford, Jonathan D Campbell, James Motyka, James D Chambers

Health Aff (Millwood)· July 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
W
What drug characteristics explain the wide range of manufacturer rebates?
Molly T Beinfeld, Fariel LaMountain, Glenn Phillips, Tom Hughes, Peter J Neumann, James D Chambers

Health Aff Sch· July 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Assessing variation in US payer coverage of anti-vascular endothelial growth factor therapies for the treatment of age-related macular degeneration, diabetic retinopathy, and diabetic macular edema.
James D Chambers, Molly T Beinfeld, Terry Richardson, Michael Pangrace

J Manag Care Spec Pharm· May 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
U
Use of health technology assessments in specialty drug coverage decisions by US commercial health plans.
Daniel E Enright, Emma G van Duijnhoven, Daniel A Ollendorf, James D Chambers

J Manag Care Spec Pharm· March 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
The Health Benefits, Costs, and Cost-Effectiveness of Ultraorphan Drugs.
Katherine A Clifford, A Alex Levine, Daniel E Enright, Peter J Neumann, James D Chambers

Value Health· December 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Are Drug Novelty Characteristics Associated With Greater Health Benefits?
A Alex Levine, Daniel E Enright, Katherine A Clifford, Stacey Kowal, James D Chambers

Appl Health Econ Health Policy· November 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Small-Molecule Drugs Offer Comparable Health Benefits To Biologics At Lower Costs.
Katherine A Clifford, A Alex Levine, Daniel E Enright, Peter J Neumann, James D Chambers

Health Aff (Millwood)· November 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
B
Balancing Evidence and Need: Variation in US Commercial Payer Coverage of Esketamine.
Ekwu B Ochigbo, Molly T Beinfeld, James D Chambers

Clin Ther· October 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
U
US Commercial Plans Increase Choice Of Biosimilar And Originator Products; Market Net Prices Decrease.
Molly T Beinfeld, Fariel LaMountain, William Wong, Eunice Kim, James D Chambers

Health Aff (Millwood)· September 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
B
Biosimilar underutilization alone does not foretell a broken biologics market.
Fariel LaMountain, Molly T Beinfeld, William Wong, Eunice Kim, James D Chambers

Health Aff Sch· July 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
U
US commercial health plan coverage dynamics in pulmonary arterial hypertension therapies.
Julia A Rucker, Molly T Beinfeld, Daniel E Enright, Hayley D Germack, Sumeet Panjabi, James D Chambers

J Manag Care Spec Pharm· June 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Improving Food and Drug Administration-Centers for Medicare and Medicaid Services Coordination for Drugs Granted Accelerated Approval.
Peter J Neumann, Elliott Crummer, James D Chambers, Sean R Tunis

Milbank Q· December 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
V
Variation in Medicaid and commercial coverage of cell and gene therapies.
Molly T Beinfeld, Julia A Rucker, Nola B Jenkins, Lucas A de Breed, James D Chambers

Health Policy Open· December 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
V
Varied use of step therapy among Medicare Advantage plans.
Nola B Jenkins, Donald E Nichols, Daniel E Enright, James D Chambers

Am J Manag Care· September 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
V
Variation in Medicaid and commercial payer coverage of aducanumab for Alzheimer's disease.
Pei-Jung Lin, Adele Levine, Julia Rucker, James D Chambers

Alzheimers Dement· August 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
F
Follow-On Indications for Orphan Drugs Related to the Inflation Reduction Act.
James D Chambers, Katherine A Clifford, Daniel E Enright, Peter J Neumann

JAMA Netw Open· August 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Commercial coverage of specialty drugs, 2017-2021.
Julia A Rucker, Molly T Beinfeld, Nola B Jenkins, Daniel E Enright, Rochelle R Henderson, James D Chambers

Health Aff Sch· August 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
F
Factors Associated with Biosimilar Exclusions and Step Therapy Restrictions Among US Commercial Health Plans.
Tianzhou Yu, Shihan Jin, Chang Li, James D Chambers, Jakub P Hlávka

BioDrugs· July 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Specialty drug coverage varies between health plans' medical and pharmacy benefit policies.
A Alex Levine, Ari D Panzer, Teresa L Kauf, Amy K O'Sullivan, Lauren Strand, James D Chambers

J Manag Care Spec Pharm· June 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Commercial health plans use of patient subgroup restrictions: An analysis of orphan and US Food and Drug Administration-expedited programs.
Nola B Jenkins, Julia A Rucker, Alexa C Klimchak, Lauren E Sedita, James D Chambers

J Manag Care Spec Pharm· May 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
The association between US Food and Drug Administration-expedited review designations and health plan specialty drug coverage.
Ari D Panzer, Michael Ingham, Silas Martin, James D Chambers

J Manag Care Spec Pharm· May 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis